NEW YORK, April 12 – DNAPrint Genomics announced Thursday that it had signed an agreement with Acculab to collect blood specimens from volunteers that can then be analyzed to determine the relationship between SNPs and particular drug reactions.
The deal is the third collaboration DNAPrint Genomics of Sarasota, Fla., has forged in its effort to collect blood samples from Florida residents.
“The average geriatric person in Florida takes an average of five drugs and we’ve developed a software based on artificial intelligence that draws associations between genetic makeup and drug response,” said Richard Craig Hall, a company spokesman.
DNAPrint, which has sample collection deals with the University of Miami and a consortium of doctors in Jacksonville, Fla., will set up kiosks in four regional Acculabs. Florida residents visiting Acculabs for tests will be solicited to voluntarily donate their blood.
Hall said the company would use the information to create diagnostics. Last October, Orchid BioSciences purchased an option for the exclusive rights to co-develop and co-commercialize DNAPrint Genomics’ SNP-disease associations. DNAPrint Genomics uses Orchis’s SNPstream system for analyzing up to 25,000 SNPs a day.
One group of drugs DNAPrint Genomics is currently investigating is statins. The anti-cholesterol drug Lipitor, which belongs to this class of drugs, requires users to visit a doctor once a week to make sure that they aren’t experiencing liver damage, Hall said.
“We feel that if we can identify the gene and the anomalies that lead to this reaction, we could take that information and make a diagnostic,” said Hall.